drugset
drugset / Trial / NCT01712919

Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

NCT01712919 ↗

Phase 1/2 Completed 61 enrolled Jiangsu Cancer Institute & Hospital
NaSingle-groupOpen-labelTreatment

Summary

The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.

Timeline

Start
2010-05
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody — —
Background Nedaplatin Small molecule — —
Background Paclitaxel Small molecule — —

Indications

nasopharyngeal carcinoma